

---

**From:** William Wallace <mammothgroup@yahoo.com>

**Sent:** Tuesday, January 12, 2021 11:43 AM

**To:** Jennifer Kreitz <jkreitz@mono.ca.gov>; rhonda.duggan@icloud.com; Bob Gardner <bgardner@mono.ca.gov>; John Peters <jpeters@mono.ca.gov>; Stacy Corless <scorless@mono.ca.gov>; Tim Kendall <tkendall@mono.ca.gov>; Queenie Barnard <qbarnard@mono.ca.gov>

**Subject:** The Covid-19 "Vaccines" do not meet the legal definition of Vaccine

**CAUTION:** This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Attention Mono County Board of Supervisors, please review this information and share it with the public so as to promote informed decision making. Please know that promoting these "Vaccines" is a violation of federal statutes. Please add this email as a standalone supporting document for today's board meeting 1/12/20. Agenda item 7.A and 7.B are the relevant items.

-Mammoth Group

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.

- Definition of Vaccine

<https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm>


- Immunity: Protection from an infectious disease. If you are immune to a disease, you can be exposed to it without becoming infected.

- Vaccine: A product that stimulates a person's immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through

needle injections, but can also be administered by mouth or sprayed into the nose.

The primary endpoint is the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease and prevention of infection by SARS-CoV-2.”

[Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.](#)



**Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint...**

First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical c...

“As of this writing, no correlate of protection for SARS-CoV-2 has been established.”

<https://www.nejm.org/doi/full/10.1056/NEJMoa2028436>

•“No existing vaccines have been shown to be effective against infection with any betacoronavirus, the family that includes SARS-CoV-2, which causes Covid-19.” Polack FP, Thomas

SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615.

[https://www.youtube.com/watch?v=p\\_hwJkhNo9w&t=1251s&ab\\_channel=DavidMartinWorld](https://www.youtube.com/watch?v=p_hwJkhNo9w&t=1251s&ab_channel=DavidMartinWorld)